Browse Studies — Arctuva

Phase 2

A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)

Open label, randomized study in patients with LaBCC not eligible or refusing surgery or radiation therapy according to the evaluation of a local interdisciplin…

Locally Advanced Basal Cell Carcinoma

Estimated

~$10 – $7,500

Philogen S.p.A.NCT07227350

Phase 2

A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Basal Cell Carcinoma Patients Progressing or Intolerant to Systemic Treatment.

Open-label, single-arm, multicentre study in patients with locally advanced BCC amenable to intratumoral injection, who have progressed on or are intolerant to…

Locally Advanced Basal Cell Carcinoma

Estimated

~$10 – $7,500

Philogen S.p.A.NCT07227870

Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study

This study evaluates the time spent on obtaining insurance approval and drugs, means of insurance coverage, out-of-pocket costs for patients, and the surgical …

Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8+5 more

Estimated

~$10 – $750

Ohio State University Comprehensive Cancer CenterNCT07215988

Phase 2

Neoadjuvant REGN2810 (Cemiplimab) or REGN2810 (Cemiplimab) Plus REGN3767 (Fianlimab) in Cutaneous Basal Cell Carcinoma of the Head and Neck

A non-randomized two-cohort study of neoadjuvant Cemiplimab or neoadjuvant Cemiplimab plus Fianlimab (CF) in patients with basal cell carcinoma of the head and…

Locally Advanced Basal Cell CarcinomaBasal Cell Carcinoma

Estimated

~$10 – $6,250

Thomas Jefferson UniversityNCT05929664